XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 51,720 $ 95,883
Marketable securities available-for-sale 609,616 617,951
Accounts receivables, net of allowance for doubtful accounts of $12,313 at March 31, 2025 and December 31, 2024, respectively 54,925 45,281
Other receivables 1,632 1,625
Inventories 74,403 70,054
Prepaid expenses and other current assets 23,674 18,147
Total current assets 815,970 848,941
Property and equipment, net 43,272 39,001
Operating lease right-of-use assets 20,869 21,608
Goodwill 2,027 1,946
Other assets, net of allowance for doubtful accounts of $10,970 at March 31, 2025 63,790 74,760
Total assets 945,928 986,256
Current liabilities:    
Accounts payable 4,330 9,061
Accrued research and development 5,654 4,310
Accrued liabilities 54,292 61,066
Other current liabilities 4,103 4,197
Total current liabilities 68,379 78,634
Convertible Notes, net of debt discount of $4,701 and $1,646 at March 31, 2025 and December 31, 2024, respectively (Note 7) 260,507 223,854
Long-term portion of lease liabilities 25,521 26,388
CEPI accrual long-term (Note 6) 60,337 60,337
Other long-term liabilities 243 244
Total liabilities 414,987 389,457
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock: $0.001 par value, 5,000 shares authorized at March 31, 2025 and December 31, 2024; zero shares outstanding at March 31, 2025 and December 31, 2024 0 0
Common stock: $0.001 par value, 278,000 shares authorized at March 31, 2025 and December 31, 2024; 123,697 shares and 125,450 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 124 125
Additional paid-in capital 1,532,835 1,504,671
Accumulated other comprehensive loss (2,644) (4,722)
Accumulated deficit (999,374) (903,275)
Total stockholders’ equity 530,941 596,799
Total liabilities and stockholders’ equity $ 945,928 $ 986,256